ZA200206039B - Novel antibody with specificity for colon cancer. - Google Patents
Novel antibody with specificity for colon cancer. Download PDFInfo
- Publication number
- ZA200206039B ZA200206039B ZA200206039A ZA200206039A ZA200206039B ZA 200206039 B ZA200206039 B ZA 200206039B ZA 200206039 A ZA200206039 A ZA 200206039A ZA 200206039 A ZA200206039 A ZA 200206039A ZA 200206039 B ZA200206039 B ZA 200206039B
- Authority
- ZA
- South Africa
- Prior art keywords
- binding
- binding structure
- target structure
- structure according
- tumour
- Prior art date
Links
- 206010009944 Colon cancer Diseases 0.000 title description 64
- 208000029742 colonic neoplasm Diseases 0.000 title description 46
- 206010028980 Neoplasm Diseases 0.000 claims description 129
- 230000027455 binding Effects 0.000 claims description 120
- 238000009739 binding Methods 0.000 claims description 120
- 210000001519 tissue Anatomy 0.000 claims description 108
- 210000004027 cell Anatomy 0.000 claims description 99
- 238000000034 method Methods 0.000 claims description 76
- 239000000427 antigen Substances 0.000 claims description 71
- 108091007433 antigens Proteins 0.000 claims description 71
- 102000036639 antigens Human genes 0.000 claims description 71
- 241000282414 Homo sapiens Species 0.000 claims description 43
- 210000004881 tumor cell Anatomy 0.000 claims description 41
- 230000003211 malignant effect Effects 0.000 claims description 34
- 239000000126 substance Substances 0.000 claims description 31
- 210000000981 epithelium Anatomy 0.000 claims description 23
- 230000014509 gene expression Effects 0.000 claims description 22
- 201000010099 disease Diseases 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 238000000338 in vitro Methods 0.000 claims description 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 16
- 238000001727 in vivo Methods 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 16
- 150000001413 amino acids Chemical class 0.000 claims description 15
- 210000000481 breast Anatomy 0.000 claims description 15
- 230000003302 anti-idiotype Effects 0.000 claims description 14
- 238000004393 prognosis Methods 0.000 claims description 13
- 230000005847 immunogenicity Effects 0.000 claims description 12
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 11
- 230000000112 colonic effect Effects 0.000 claims description 11
- 238000003745 diagnosis Methods 0.000 claims description 11
- 210000000110 microvilli Anatomy 0.000 claims description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 11
- 239000000523 sample Substances 0.000 claims description 11
- 210000004072 lung Anatomy 0.000 claims description 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 9
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 9
- 210000002919 epithelial cell Anatomy 0.000 claims description 9
- 230000000762 glandular Effects 0.000 claims description 9
- 201000005296 lung carcinoma Diseases 0.000 claims description 9
- 201000001441 melanoma Diseases 0.000 claims description 9
- 239000002245 particle Substances 0.000 claims description 9
- 230000002829 reductive effect Effects 0.000 claims description 9
- 208000026310 Breast neoplasm Diseases 0.000 claims description 8
- 239000012188 paraffin wax Substances 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 238000002560 therapeutic procedure Methods 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 6
- 210000001124 body fluid Anatomy 0.000 claims description 6
- 201000008275 breast carcinoma Diseases 0.000 claims description 6
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- 210000003734 kidney Anatomy 0.000 claims description 6
- 210000000496 pancreas Anatomy 0.000 claims description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 6
- 210000000952 spleen Anatomy 0.000 claims description 6
- 241000288906 Primates Species 0.000 claims description 5
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 5
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 5
- 210000004185 liver Anatomy 0.000 claims description 5
- 210000003491 skin Anatomy 0.000 claims description 5
- 210000001685 thyroid gland Anatomy 0.000 claims description 5
- 241000282412 Homo Species 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 210000002808 connective tissue Anatomy 0.000 claims description 4
- 231100000433 cytotoxic Toxicity 0.000 claims description 4
- 230000001472 cytotoxic effect Effects 0.000 claims description 4
- 230000028993 immune response Effects 0.000 claims description 4
- 230000001394 metastastic effect Effects 0.000 claims description 4
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 238000012216 screening Methods 0.000 claims description 4
- 241000282567 Macaca fascicularis Species 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 239000006285 cell suspension Substances 0.000 claims description 3
- 230000004807 localization Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 210000004165 myocardium Anatomy 0.000 claims description 3
- 229960005486 vaccine Drugs 0.000 claims description 3
- 102000053642 Catalytic RNA Human genes 0.000 claims description 2
- 108090000994 Catalytic RNA Proteins 0.000 claims description 2
- 108091034117 Oligonucleotide Proteins 0.000 claims description 2
- 208000006994 Precancerous Conditions Diseases 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 2
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 2
- 230000000747 cardiac effect Effects 0.000 claims description 2
- 230000021615 conjugation Effects 0.000 claims description 2
- 238000012333 histopathological diagnosis Methods 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 claims description 2
- 210000003205 muscle Anatomy 0.000 claims description 2
- 201000010174 renal carcinoma Diseases 0.000 claims description 2
- 108091092562 ribozyme Proteins 0.000 claims description 2
- 229940000425 combination drug Drugs 0.000 claims 1
- 230000009977 dual effect Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 34
- 210000001072 colon Anatomy 0.000 description 33
- 238000010186 staining Methods 0.000 description 31
- 230000009257 reactivity Effects 0.000 description 30
- 239000000463 material Substances 0.000 description 26
- 238000006243 chemical reaction Methods 0.000 description 23
- 238000001179 sorption measurement Methods 0.000 description 21
- 108020001507 fusion proteins Proteins 0.000 description 20
- 102000037865 fusion proteins Human genes 0.000 description 20
- 102000004169 proteins and genes Human genes 0.000 description 19
- 235000018102 proteins Nutrition 0.000 description 15
- 210000004291 uterus Anatomy 0.000 description 14
- 238000005516 engineering process Methods 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 8
- 206010027476 Metastases Diseases 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 238000011579 SCID mouse model Methods 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 238000001493 electron microscopy Methods 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 6
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 229960002685 biotin Drugs 0.000 description 6
- 239000011616 biotin Substances 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 230000036046 immunoreaction Effects 0.000 description 6
- 238000000386 microscopy Methods 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 5
- 201000010989 colorectal carcinoma Diseases 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 239000012909 foetal bovine serum Substances 0.000 description 5
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 5
- 238000003364 immunohistochemistry Methods 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 238000003375 selectivity assay Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 231100000617 superantigen Toxicity 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 229960005091 chloramphenicol Drugs 0.000 description 4
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 4
- 230000002055 immunohistochemical effect Effects 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108010033276 Peptide Fragments Proteins 0.000 description 3
- 102000007079 Peptide Fragments Human genes 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 3
- 238000001261 affinity purification Methods 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 231100000655 enterotoxin Toxicity 0.000 description 3
- 210000001703 glandular epithelial cell Anatomy 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 238000002823 phage display Methods 0.000 description 3
- 230000004481 post-translational protein modification Effects 0.000 description 3
- 238000010187 selection method Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 101100224495 Drosophila melanogaster Chrac-14 gene Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 2
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 101100084022 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) lapA gene Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 108010007093 dispase Proteins 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000727 fraction Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- DWCZIOOZPIDHAB-UHFFFAOYSA-L methyl green Chemical compound [Cl-].[Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC(=CC=1)[N+](C)(C)C)=C1C=CC(=[N+](C)C)C=C1 DWCZIOOZPIDHAB-UHFFFAOYSA-L 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 101150009573 phoA gene Proteins 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 1
- LXJXRIRHZLFYRP-VKHMYHEASA-L (R)-2-Hydroxy-3-(phosphonooxy)-propanal Natural products O=C[C@H](O)COP([O-])([O-])=O LXJXRIRHZLFYRP-VKHMYHEASA-L 0.000 description 1
- FJQZXCPWAGYPSD-UHFFFAOYSA-N 1,3,4,6-tetrachloro-3a,6a-diphenylimidazo[4,5-d]imidazole-2,5-dione Chemical compound ClN1C(=O)N(Cl)C2(C=3C=CC=CC=3)N(Cl)C(=O)N(Cl)C12C1=CC=CC=C1 FJQZXCPWAGYPSD-UHFFFAOYSA-N 0.000 description 1
- HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 1
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 108090000145 Bacillolysin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- LXJXRIRHZLFYRP-VKHMYHEASA-N D-glyceraldehyde 3-phosphate Chemical compound O=C[C@H](O)COP(O)(O)=O LXJXRIRHZLFYRP-VKHMYHEASA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 101100117236 Drosophila melanogaster speck gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 240000001327 Echinochloa stagnina Species 0.000 description 1
- 235000001418 Echinochloa stagnina Nutrition 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 235000001797 Lavandula macra Nutrition 0.000 description 1
- 235000001803 Lavandula setifera Nutrition 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 108010008707 Mucin-1 Proteins 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 102000035092 Neutral proteases Human genes 0.000 description 1
- 108091005507 Neutral proteases Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101710115215 Protease inhibitors Proteins 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010053614 Type III immune complex mediated reaction Diseases 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000000961 alloantigen Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002494 anti-cea effect Effects 0.000 description 1
- 230000003127 anti-melanomic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 230000000981 bystander Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 229940077731 carbohydrate nutrients Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 230000000332 continued effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 108010021083 hen egg lysozyme Proteins 0.000 description 1
- 230000016178 immune complex formation Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940051875 mucins Drugs 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 210000001986 peyer's patch Anatomy 0.000 description 1
- 208000016021 phenotype Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 229940070376 protein Drugs 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 229940072172 tetracycline antibiotic Drugs 0.000 description 1
- 230000009258 tissue cross reactivity Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0000597A SE0000597D0 (sv) | 2000-02-24 | 2000-02-24 | Novel antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200206039B true ZA200206039B (en) | 2003-07-29 |
Family
ID=20278567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200206039A ZA200206039B (en) | 2000-02-24 | 2002-07-29 | Novel antibody with specificity for colon cancer. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US7425623B2 (zh) |
| EP (1) | EP1257291A1 (zh) |
| JP (1) | JP2003523213A (zh) |
| KR (1) | KR20020079888A (zh) |
| CN (1) | CN1406136A (zh) |
| AU (1) | AU775876B2 (zh) |
| BR (1) | BR0108609A (zh) |
| CA (1) | CA2400661A1 (zh) |
| EE (1) | EE200200473A (zh) |
| HK (1) | HK1052648A1 (zh) |
| HU (1) | HUP0300007A3 (zh) |
| IL (1) | IL151325A0 (zh) |
| MX (1) | MXPA02008315A (zh) |
| NO (1) | NO20023670L (zh) |
| NZ (1) | NZ520523A (zh) |
| PL (1) | PL356386A1 (zh) |
| RU (1) | RU2268068C2 (zh) |
| SE (1) | SE0000597D0 (zh) |
| SK (1) | SK11982002A3 (zh) |
| WO (1) | WO2001062286A1 (zh) |
| YU (1) | YU63702A (zh) |
| ZA (1) | ZA200206039B (zh) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2450692A1 (en) * | 2001-06-12 | 2003-01-30 | Kyogo Itoh | Tumor antigen |
| US20030206916A1 (en) | 2002-05-03 | 2003-11-06 | Rush-Presbyterian-St. Luke's Medical Center | Immunogenic peptides |
| CN1303105C (zh) * | 2003-12-08 | 2007-03-07 | 陈志南 | 抗人大肠癌单克隆抗体CAb—2轻、重链可变区基因及其应用 |
| EP2044120B1 (en) * | 2006-06-07 | 2019-01-30 | BioAlliance C.V. | Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same |
| EP2048241B1 (en) * | 2007-10-08 | 2012-07-25 | Sividon Diagnostics GmbH | Method employing GAPDH as molecular markers for cancer prognosis |
| RU2528738C2 (ru) * | 2007-12-18 | 2014-09-20 | Биоэллаенс К.В. | Антитела, узнающие углеводсодержащий эпитоп на cd43 и сеа, экспрессируемых на раковых клетках и способы их применения |
| CN104698168A (zh) * | 2008-09-01 | 2015-06-10 | 国立大学法人名古屋大学 | 抗癌剂作用增强剂及其应用、以及癌患者预后推定用生物标记物及其应用 |
| FR2945952B1 (fr) * | 2009-05-27 | 2013-10-04 | Univ Claude Bernard Lyon | Anticorps anti-ck8 pour utilisation comme medicament. |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5798257A (en) * | 1990-07-09 | 1998-08-25 | Research Corporation Technologies, Inc. | Nucleic acid encoding human MTS-1 protein |
| US5994088A (en) * | 1991-03-08 | 1999-11-30 | Board Of Trustees Of The University Of Illinois | Methods and reagents for preparing and using immunological agents specific for P-glycoprotein |
| IL106610A0 (en) * | 1992-08-07 | 1993-12-08 | Cytel Corp | Hla binding peptides and their uses |
| US5972643A (en) * | 1994-06-17 | 1999-10-26 | Fred Hutchinson Cancer Research Center | Isolated polynucleotide molecules encoding CTCF, a CCCTC-binding factor |
| WO1997002479A2 (en) * | 1995-06-30 | 1997-01-23 | Yale University | Human monoclonal anti-tumor antibodies |
| CA2241564C (en) * | 1996-01-08 | 2013-09-03 | Genentech, Inc. | Wsx receptor and ligands |
| WO1998003411A1 (fr) | 1996-07-18 | 1998-01-29 | Montania | Bouchon avec recipient auxiliaire et procede de realisation |
| DE69718341T2 (de) * | 1996-10-08 | 2003-10-30 | Bisys B V U | Verfahren und mittel zur auswahl von peptiden und proteinen mit spezifischer affinität zu einem zielmolekül |
| SE9700291D0 (sv) * | 1997-01-31 | 1997-01-31 | Pharmacia & Upjohn Ab | Selection method and prodcts resulting therefrom |
| ES2246069T3 (es) * | 1997-05-02 | 2006-02-01 | Genentech, Inc. | Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos. |
| WO1999010485A1 (en) * | 1997-08-29 | 1999-03-04 | Selective Genetics, Inc. | Methods using phage display for selecting internalizing ligands for gene delivery |
| DE19739525A1 (de) * | 1997-09-09 | 1999-09-30 | Heinrich Abbrederis | Die Vorrichtung T.C.Reinigungskopf ermöglicht die Reinigung, Schmierung und Konservierung von Ketten im eingebauten und ausgebauten Zustand unter minimalen Platzverhältnissen |
| CA2253633A1 (en) * | 1997-12-03 | 1999-06-03 | Boehringer Mannheim Corporation | Complex specific antibodies, method of preparation and uses thereof |
| AU770952B2 (en) * | 1999-03-01 | 2004-03-11 | Genentech Inc. | Antibodies for cancer therapy and diagnosis |
-
2000
- 2000-02-24 SE SE0000597A patent/SE0000597D0/xx unknown
-
2001
- 2001-02-23 IL IL15132501A patent/IL151325A0/xx unknown
- 2001-02-23 KR KR1020027010963A patent/KR20020079888A/ko not_active Application Discontinuation
- 2001-02-23 NZ NZ520523A patent/NZ520523A/en unknown
- 2001-02-23 AU AU36294/01A patent/AU775876B2/en not_active Ceased
- 2001-02-23 SK SK1198-2002A patent/SK11982002A3/sk not_active Application Discontinuation
- 2001-02-23 MX MXPA02008315A patent/MXPA02008315A/es unknown
- 2001-02-23 CA CA002400661A patent/CA2400661A1/en not_active Abandoned
- 2001-02-23 EP EP01908551A patent/EP1257291A1/en not_active Withdrawn
- 2001-02-23 EE EEP200200473A patent/EE200200473A/xx unknown
- 2001-02-23 CN CN01805577A patent/CN1406136A/zh active Pending
- 2001-02-23 RU RU2002125386/15A patent/RU2268068C2/ru not_active IP Right Cessation
- 2001-02-23 JP JP2001561350A patent/JP2003523213A/ja not_active Withdrawn
- 2001-02-23 YU YU63702A patent/YU63702A/sh unknown
- 2001-02-23 BR BR0108609-0A patent/BR0108609A/pt not_active IP Right Cessation
- 2001-02-23 WO PCT/SE2001/000395 patent/WO2001062286A1/en active IP Right Grant
- 2001-02-23 US US10/182,132 patent/US7425623B2/en not_active Expired - Fee Related
- 2001-02-23 HU HU0300007A patent/HUP0300007A3/hu unknown
- 2001-02-23 PL PL01356386A patent/PL356386A1/xx not_active Application Discontinuation
-
2002
- 2002-07-29 ZA ZA200206039A patent/ZA200206039B/en unknown
- 2002-08-02 NO NO20023670A patent/NO20023670L/no not_active Application Discontinuation
-
2003
- 2003-07-09 HK HK03104939.3A patent/HK1052648A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2003523213A (ja) | 2003-08-05 |
| BR0108609A (pt) | 2002-11-19 |
| WO2001062286A1 (en) | 2001-08-30 |
| AU3629401A (en) | 2001-09-03 |
| EP1257291A1 (en) | 2002-11-20 |
| YU63702A (sh) | 2006-01-16 |
| MXPA02008315A (es) | 2002-12-09 |
| CA2400661A1 (en) | 2001-08-30 |
| RU2002125386A (ru) | 2004-03-20 |
| IL151325A0 (en) | 2003-04-10 |
| NO20023670L (no) | 2002-08-23 |
| NO20023670D0 (no) | 2002-08-02 |
| CN1406136A (zh) | 2003-03-26 |
| HUP0300007A2 (en) | 2003-05-28 |
| AU775876B2 (en) | 2004-08-19 |
| SK11982002A3 (sk) | 2003-03-04 |
| NZ520523A (en) | 2004-08-27 |
| RU2268068C2 (ru) | 2006-01-20 |
| EE200200473A (et) | 2004-02-16 |
| SE0000597D0 (sv) | 2000-02-24 |
| US20030176661A1 (en) | 2003-09-18 |
| HK1052648A1 (zh) | 2003-09-26 |
| KR20020079888A (ko) | 2002-10-19 |
| PL356386A1 (en) | 2004-06-28 |
| HUP0300007A3 (en) | 2005-11-28 |
| US7425623B2 (en) | 2008-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7189816B1 (en) | Compounds | |
| US7244826B1 (en) | Internalizing ERB2 antibodies | |
| EP0521842B1 (en) | Tumor antigen specific antibody | |
| Zhang et al. | A pentavalent single-domain antibody approach to tumor antigen discovery and the development of novel proteomics reagents | |
| JP2008505645A (ja) | ガン細胞に特異的な抗体を見出すための方法およびそれによって見出される抗体 | |
| MXPA05011368A (es) | Anticuerpos recombinantes y fragmentos que reconocen el gangliosido n-glicolil gm3 y su uso para diagnostico y tratamiento de tumores. | |
| MXPA04004857A (es) | ANTICUERPOS DE COLáGENA HUMANIZADOS Y METODOS RELACIONADOS. | |
| US20070042447A1 (en) | Use of anti-ferritin monoclonal antibodies in the treatment of some cancers (divisional) | |
| US8741296B2 (en) | Adenocarcinoma specific antibody SAM-6, and uses thereof | |
| US7425623B2 (en) | Antibody with specificity for colon cancer | |
| Xu et al. | Production of a human single-chain variable fragment antibody against esophageal carcinoma | |
| JP2003527334A (ja) | Ａ３３抗原特異的免疫グロブリン産物を用いるａ３３抗原を発現する癌の影響を低減する方法 | |
| Roovers et al. | Identification of colon tumour-associated antigens by phage antibody selections on primary colorectal carcinoma | |
| EP4063387A1 (en) | Psma antibody and use thereof | |
| AU6883700A (en) | Melanoma associated antigen (hmw-maa) defined by a monoclonal antibody | |
| Pimenidou et al. | Bacteriophage-Derived Antibodies in Cancer Research—Diagnosis, Imaging, and Treatment | |
| AU2005221470A1 (en) | Inhibitors of extracellular hsp90 | |
| BARAL et al. | Patent 2813133 Summary |